Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Soleno Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company ...

Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have received a consensus recommendation of “Buy” from the seven research firms that are covering the company, MarketBeat.com ...

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

REDWOOD CITY, CA—Soleno Therapeutics Inc. (NASDAQ:SLNO), a $1.98 billion market cap biopharmaceutical company, recently disclosed a series of stock sales by Kristen Yen, the company's Senior Vice ...

Patricia Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (NASDAQ:SLNO), recently sold shares of the company. According to a filing with the Securities and Exchange ...

Anish Bhatnagar, the Chief Executive Officer of Soleno Therapeutics Inc. (NASDAQ:SLNO), recently sold a significant portion of the company's stock. According to an SEC filing, Bhatnagar sold a total ...